hyperimmune intravenous immunoglobulin G specific to SARS-CoV-2

Hyperimmune intravenous immunoglobulin G specific to SARS-CoV-2, marketed as Covimmune™, is a polyclonal hyperimmune intravenous immunoglobulin (HIVIG) developed by the Australian company Aegros Ltd. It is produced from pooled human plasma collected from donors who have recovered from COVID-19 (convalescent plasma). The manufacturing process utilizes Aegros' proprietary HaemaFrac™ technology, a high-volume electrophoresis-based plasma fractionation method that achieves high purity and protein yield. The drug contains a concentrated solution of purified IgG antibodies with high titers of neutralizing antibodies against the SARS-CoV-2 virus. It is designed to provide immediate passive immunity for the prevention and treatment of COVID-19, particularly in vulnerable populations such as the immunocompromised or frontline workers. In the Phase 1/2 CHAT clinical trial, Covimmune™ demonstrated a fourfold increase in peak antibody levels compared to convalescent plasma and maintained a favorable safety profile.

Brand names

Covimmune

Other names

anti-SARS-CoV-2 hyperimmune immunoglobulinanti-SARS-CoV2 hyperimmune immunoglobulinanti-SARS-CoV 2 hyperimmune immunoglobulinCOVID-19 hyperimmune immunoglobulinCOVID19 hyperimmune immunoglobulinCOVID 19 hyperimmune immunoglobulinHIVIG